Çubukcu, ErdemŞahin, Ahmet BilgehanAtalay, Fatma ÖzOcak, BirolÖzşen, MineAbakay, Candan DemirözÖzerkan, KemalHasanzade, UlviyyaMesahorlı, MerveDeligönül, AdemOzan, HakanEvrensel, Türkkan2024-06-252024-06-252021-04-210392-2936https://doi.org/10.31083/j.ejgo4204117https://www.ejgo.net/articles/10.31083/j.ejgo4204117https://hdl.handle.net/11452/42369Objective: To investigate the prognostic factors comparing clinical, histopathological, and laboratory parameters in low-risk endometrial cancer (EC). Methods: In the present single-center study, multivariate Cox regression analysis was performed on retrospective clinical and laboratory data and histopathological features obtained from the re-evaluation of 253 patients with low-risk EC. Receiver operating characteristic curves (ROC) were plotted for neutrophile-lymphocyte ratio (NLR), platelet-lymphocyte ratio, lymphocyte-monocyte ratio and Ki-67 index for recurrence. Kaplan-Meier analysis was employed for survival rates. Results: The median age was 58.5 years (32.0-75.4). Most of the patients were obese and post-menopausal. In nearly half of the patients, lymphadenectomy was performed in addition to hysterectomy and oophorectomy. The median tumor size was 30 mm (range 2-80), and the median Ki-67 index was 25 (1-90). According to the ROC curve analysis, the cut-off values for the Ki-67 index, NLR, PLR, and LMR were determined as >= 22, >= 1.98, >= 115.3, and >= 4.71, respectively. The log-rank test revealed that the patients with a Ki67 index lower than 22% and NLR lower than 1.98 had statistically longer recurrence-free survival (RFS) (p = 0.002 for Ki-67 index and p = 0.004 for NLR). The multivariate analysis revealed that the Ki-67 index and NLR were statistically significant factors for RFS (p = 0.012 and p = 0.029, respectively). Conclusion: The present study highlights the prognostic implications of both the Ki-67 index and NLR in lowrisk EC.eninfo:eu-repo/semantics/openAccessCell proliferationExpressionImpactRolesKi67P53PREREndometrial cancerLow-riskKi-67NLRSurvivalOncologyObstetrics & gynecologyArticle00068663940002477578142410.31083/j.ejgo42041172709-0086